STCube

STCube P/B

The P/B (Price-to-Book Ratio) of STCube (052020.KQ) as of Oct 24, 2026 is 15.35. In the previous year, P/B (Price-to-Book Ratio) was 11.75 — a change of 30.72% (higher).

P/B

15.35

YoY

30.72%

Last updated:

P/B (Price-to-Book Ratio) of STCube is 2025 15.35 . P/B (Price-to-Book Ratio) of STCube was 2024 11.75 . It decreases by 30.72% higher compared to the previous year.

The STCube P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
28.61 KRW
Jan 1, 2019
38.43 KRW
Jan 1, 2020
30.74 KRW
Jan 1, 2021
68.50 KRW
Jan 1, 2022
21.62 KRW
Jan 1, 2023
31.36 KRW
Jan 1, 2024
11.75 KRW
Jan 1, 2025
15.35 KRW
The STCube P/B history
YEARP/BYoY
15.35+30.72%
11.75-62.55%
31.36+45.06%
21.62-68.44%
68.50+122.87%
30.74-20.01%
38.43+34.31%
28.61-50.59%
57.91+52.92%
37.87-28.48%
52.95+2.62%
51.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

P/B (Price-to-Book Ratio) of STCube is 15.35 in 2025.

P/B (Price-to-Book Ratio) of STCube changed from 11.75 to 15.35, representing a 30.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) STCube since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — STCube

All Key Metrics — STCube